IDH1 and neoplasm: It has been identified that one of the mechanisms given by this favorable outcome is the impaired production of nicotinamide adenine dinucleotide phosphate in Krebs cycle caused by IDH1 enzyme mutation that can sensitize tumor cells to chemotherapy and explain the favorable prognosis of patients with IDH mutation [25].